| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
|
N Engl J Med
|
2010
|
27.12
|
|
2
|
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.
|
Clin Cancer Res
|
2004
|
4.65
|
|
3
|
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1.
|
Nat Immunol
|
2012
|
3.57
|
|
4
|
Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells.
|
Proc Natl Acad Sci U S A
|
2011
|
2.08
|
|
5
|
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
|
BMC Cancer
|
2007
|
1.85
|
|
6
|
CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers.
|
Cancer Sci
|
2003
|
1.78
|
|
7
|
Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
|
Cancer
|
2010
|
1.27
|
|
8
|
Expression of LGR5, an intestinal stem cell marker, during each stage of colorectal tumorigenesis.
|
Anticancer Res
|
2011
|
1.24
|
|
9
|
Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings.
|
Respiration
|
2003
|
1.17
|
|
10
|
Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
|
Lung Cancer
|
2012
|
1.15
|
|
11
|
Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.
|
Lung Cancer
|
2006
|
1.13
|
|
12
|
Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorage-independent growth in RAT1a cells.
|
J Biol Chem
|
2005
|
1.02
|
|
13
|
AP-1 complexes containing cJun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets.
|
Oncogene
|
2003
|
1.01
|
|
14
|
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
|
Oncologist
|
2012
|
0.98
|
|
15
|
[Superior vena cava syndrome].
|
Gan To Kagaku Ryoho
|
2011
|
0.96
|
|
16
|
CD133 expression: a potential prognostic marker for non-small cell lung cancers.
|
Int J Clin Oncol
|
2013
|
0.96
|
|
17
|
Increased expression of beta-catenin predicts better prognosis in nonsmall cell lung carcinomas.
|
Cancer
|
2002
|
0.94
|
|
18
|
Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4.
|
Cancer Med
|
2014
|
0.93
|
|
19
|
Epithelioid sarcoma presenting as pulmonary cysts with cancer antigen 125 expression.
|
Respirology
|
2006
|
0.93
|
|
20
|
CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential.
|
Oncogene
|
2002
|
0.93
|
|
21
|
Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.
|
Oncology
|
2011
|
0.92
|
|
22
|
E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells.
|
Cancer Res
|
2005
|
0.92
|
|
23
|
Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer.
|
Lung Cancer
|
2010
|
0.91
|
|
24
|
Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice.
|
Hum Gene Ther
|
2003
|
0.91
|
|
25
|
ATM-mediated DNA damage signals mediate immune escape through integrin-αvβ3-dependent mechanisms.
|
Cancer Res
|
2011
|
0.90
|
|
26
|
Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.
|
Anticancer Res
|
2005
|
0.87
|
|
27
|
Expression of N-acetylglucosaminyltransferase V in the development of human esophageal cancers: immunohistochemical data from carcinomas and nearby noncancerous lesions.
|
Oncology
|
2005
|
0.86
|
|
28
|
Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers.
|
Cancer Sci
|
2003
|
0.86
|
|
29
|
18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts.
|
Oncol Rep
|
2011
|
0.84
|
|
30
|
Retinoic acid inhibits interleukin-4-induced eotaxin production in a human bronchial epithelial cell line.
|
Am J Physiol Lung Cell Mol Physiol
|
2003
|
0.82
|
|
31
|
Clinicopathological significance of expression of p-c-Jun, TCF4 and beta-Catenin in colorectal tumors.
|
BMC Cancer
|
2008
|
0.82
|
|
32
|
Expression of Bim, Noxa, and Puma in non-small cell lung cancer.
|
BMC Cancer
|
2012
|
0.81
|
|
33
|
Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.
|
Cancer Chemother Pharmacol
|
2014
|
0.80
|
|
34
|
Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.
|
Oncology
|
2011
|
0.80
|
|
35
|
A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.
|
Oncologist
|
2013
|
0.79
|
|
36
|
High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers. Association with clinicopathological parameters.
|
Oncology
|
2007
|
0.79
|
|
37
|
Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer.
|
Lung Cancer
|
2011
|
0.79
|
|
38
|
Increase in soluble CD138 in bronchoalveolar lavage fluid of multicentric Castleman's disease.
|
Respirology
|
2007
|
0.79
|
|
39
|
Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.
|
Anticancer Res
|
2006
|
0.78
|
|
40
|
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
|
Int J Clin Oncol
|
2014
|
0.78
|
|
41
|
Expression of fucosyltransferase 8 is associated with an unfavorable clinical outcome in non-small cell lung cancers.
|
Oncology
|
2015
|
0.78
|
|
42
|
Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer.
|
Jpn J Clin Oncol
|
2004
|
0.78
|
|
43
|
A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy.
|
Case Rep Oncol
|
2011
|
0.78
|
|
44
|
Paraneoplastic cerebellar degeneration (PCD) associated with squamous cell carcinoma of the lung.
|
Intern Med
|
2004
|
0.75
|
|
45
|
Establishment and characterization of amylase-producing lung adenocarcinoma cell line, IMEC-2.
|
Anticancer Res
|
2006
|
0.75
|
|
46
|
Susceptibility to oxygen desaturation during bronchoscopy in elderly patients with pulmonary fibrosis.
|
Respiration
|
2005
|
0.75
|
|
47
|
[Non-small-cell lung cancer].
|
Gan To Kagaku Ryoho
|
2008
|
0.75
|
|
48
|
[A case of paclitaxel-induced pneumonitis].
|
Nihon Kokyuki Gakkai Zasshi
|
2004
|
0.75
|
|
49
|
[A case of Mycobacterium avium pulmonary disease detected as multiple small nodular shadows and diagnosed by CT guided transbronchial biopsy with ultrathin bronchoscopy].
|
Nihon Kokyuki Gakkai Zasshi
|
2003
|
0.75
|